Woodbridge,Ontario, Canada, September 8, 2011 - Pivotal Therapeutics Inc.(CNSX:PVO) a specialty pharmaceutical company with a focus on thetreatment of cardiovascular disease, today reported that Dr. GeorgeJackowski, Chairman and Chief Scientific Officer presented highlights ofthe Company and its research on August 31, 2011 at the BIOFLORIDASoutheast Chapter Event. The presentation was given at the Research Parkat Florida Atlantic University (FAU) in Boca Raton, Florida.
"Itwas an honour to present at the BIOFLORIDA event at the Research Parkespecially given that Pivotal's regional product commercialization anddistribution will be centered in Boca Raton." said Dr. Jackowski. "Weare very proud to have been accepted into the Florida community where wewill be launching our lead therapeutic, VASCAZENTM, in Orlando, Floridaat the American Heart Association's (AHA) Scientific Sessions 2011 thisNovember."
In June 2011, Pivotal announced the openingof its US Headquarters at the Research Park at FAU. The FloridaAtlantic Research Park is Florida's top destination for technologycompanies to thrive collaborating with the region's premier researchuniversity. Located adjacent to the main campus of FAU, the Park is inclose proximity to Scripps Florida, Torrey Pines Institute for MolecularStudies, the University of Miami Miller School of Medicine, theworld-renowned Harbor Branch Research Centre.
"Giventhe exciting developments at the Company as we move towards VASCAZEN'sTMNorth American product launch this fall, it is our intent to keep theresearch and investment communities apprised of Pivotal's progress,"says Eugene Bortoluzzi, Chief Executive Officer and Chief FinancialOfficer. "As part of those plans Pivotal will also be presenting at theprestigious Rodman & Renshaw Annual Global Investment Conference onSeptember 13th in New York."
The Canadian launch ofVASCAZENTM at the Canadian Cardiovascular Congress Vancouver 2011,hosted by the Canadian Cardiovascular Society & the Heart and StrokeFoundation of Canada, will take place from October 22 - 26 at theVancouver Convention Centre in Vancouver, Canada.
TheAmerican launch of VASCAZENTM at the AHA's Scientific Sessions 2011 willtake place from November 13-15, 2011 at the Orange County ConventionCentre in Orlando, Florida. Both conferences represent the largest andmost prestigious gathering of physicians, scientist and healthcareprofessionals.
About BIOFLORIDA (www.bioflorida.com)
BIOFLORIDAis the voice of Florida’s bioscience industry representing more than3,000 companies and research organizations in the biotechnology,pharmaceutical and medical device fields employing 61,000 Floridians.BIOFLORIDA’s member-driven initiatives provide a strong business climatefor production of quality, life-improving technologies and promoteeconomic benefits to the state. BIOFLORIDA influences the growth of theindustry through exceptional programming that offers networking andbusiness development opportunities, access to capital, and informationregarding public policy efforts.
About Pivotal Therapeutics Inc.
Withoffices in Toronto, Canada and Boca Raton, Florida, PivotalTherapeutics is a publicly traded (CNSX: PVO) specialty pharmaceuticalcompany with a focus on the treatment of cardiovascular disease. PivotalTherapeutics' lead product VASCAZENTM is a prescription medical foodformulated to meet the dietary Omega-3 deficient needs of patients withcardiovascular disease through elevating Eicosapentaenoic (EPA) andDocosahexaenoic (DHA) to levels associated with reduced risk ofcardiovascular complications.
VASCAZENTM is a >90%pure, proprietary EPA:DHA fatty acid formulation, protected by a seriesof both issued and pending US and foreign patents and commercialized byprescription only. This unique formulation will provide the cornerstoneupon which a family of cutting edge combination products, with efficacyacross a broad spectrum of cardiac care, will be commercialized.
Disclosure Notice
Theinformation contained in this document is as of September 8, 2011. Thispress release contains forward-looking statements. Such forward-lookingstatements are subject to a number of risks, assumptions anduncertainties that could cause Pivotal's actual results to differmaterially from those projected in such forward-looking statements.These statements can be identified by the use of words such as "will","anticipate", "estimate", "expect", "project", "forecast", "intend","plan", "believe", "project", "potential", and similar expressions withany discussion of future operating or financial performance or events.In particular, factors that could cause actual results to differmaterially from those in forward looking statements include thefollowing: Pivotal's inability to obtain additional financing onacceptable terms; growth in costs and expenses; inability to competewith others who provide comparable products; risk that the Company'sproducts will not gain widespread market acceptance; risks relating tothe Company's ability to maintain its CSNX listing. Forward-lookingstatements speak only as of the date made and are not guarantees offuture performance. The Company undertakes no obligation to publiclyupdate or revise any forward-looking statements. contained in thisdocument as a result of new information or future events ordevelopments.
- # -
Investor Relations Contact: Company Contact:
Timothy J. Ryan Rachelle MacSweeney
Managing Director President
Phone: 212-242-7777 Phone: 905-856-9797
E-Mail:tryan@shorehamgroupllc.comThis e-mail address is being protected fromspambots. You need JavaScript enabled to viewit. E-Mail:rmacsweeney@pivotaltherapeutics.usThis e-mail address is being protectedfrom spambots. You need JavaScript enabled to view it.
The Shoreham Group, LLC Pivotal Therapeutics Inc.
www. shorehamgroupllc.com www.pivotaltherapeutics.us
